Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
- PMID: 28001228
- DOI: 10.1590/0037-8682-0213-2016
Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
Abstract
Introduction:: Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity.
Methods: Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals.
Results: The technique is described in detail sufficient to enable replication.
Conclusions:: The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
